Glucose metabolism is of vital importance in normal brain function. Evidence indicates that glycolysis, in addition to production of ATP, plays an important role in maintaining normal synaptic function. In an effort to understand the potential involvement of a glycolytic intermediate (s) Glucose metabolism is of paramount importance in brain function. Cerebral energy is derived from glucose under normal conditions (Siesjo 1978) . Hence, the necessity for glucose in brain function had been considered solely due to ATP production. However, evidence has accumulated indicating that hypoglycemia leads to neuronal dysfunction, as judged by abnormal electroencephalogram and population spikes, as well as to abnormal behavior, long before cerebral ATP is depleted (Dirks et al. 1980; Cox and Bachelard 1982; Ghajar et al. 1982) . This suggests that sustaining global cellular ATP at the normal level would not substitute for the glucose metabolism requirement. Morino et al. (1991) 
activity-dependent increase in glucose metabolism largely occurs in the nerve terminal. We demonstrate that a 29-kDa protein is labeled as the major component in the synaptosomal cytosol (synsol) fraction, and present evidence that the labeled 29-kDa protein is monophosphoglycerate mutase (PGAM). Among non-substrate substances, fructose-2,6-bisphosphate (Fru-2,6-P 2 ) was found to affect the state of phosphorylation of the 29-kDa protein and PGAM, as well as PGAM enzyme activity. The significance of a unique subcellular and tissue distribution of the labeled 29-kDa protein observed here is also discussed, together with a potential regulatory role of Fru-2,6-P 2 in glycolysis via PGAM. [c-32 P]ATP (6000 Ci/mM) was obtained from Perkin Elmer Life Sciences (Boston, MA, USA). [ 32 P]Phosphoric acid (Pi, carrier-free) was purchased from ICN (Irvine, CA). Glycolytic enzymes, their intermediates and all other chemicals were purchased from SigmaAldrich (St Louis, MO, USA). The affinity-purified polyclonal antibody (rabbit IgG) specific to human recombinant PGAM type B (anti-PGAM pAb) was kindly provided by Oriental Yeast Co., Ltd. (Tokyo, Japan). 32 P]glyceraldehyde-3-phosphate (GAP) with triose phosphate isomerase, followed by a GAP dehydrogenase reaction in the presence of the lactate dehydrogenase-coupled NAD regenerating system. The reaction mixture (400 lL) contained 12.5 mM triethanolamine (pH 8.0), 0.2 mM EDTA, 2 mM NAD, 2 mM Na pyruvate, 2 mM KH 2 PO 4 , 50 lM DHAP, 3.2 U GAP dehydrogenase (rabbit muscle), 20 U triose phosphate isomerase (rabbit muscle), 10 U lactate dehydrogenase (rabbit muscle) and 40 lL of the [ 32 P]DHAP reaction mixture. The entire mixture was incubated at 25°C for 5 min. For synthesis of [ 32 P]3-PG, a reaction was performed under the same conditions, except that 0.5 U 3-PG kinase (Saccharomyces cerevisiae) was added to, and EDTA removed from, the above reaction mixture. Each reaction mixture was filtered to remove the enzymes by an Amicon Centricon-10 concentrator (Amicon, Danvers, MA, USA) and put onto a DEAEcellulose column (Whatman DE32, 1.2 · 2.2 cm; Watman Inc., Clifton, NJ, USA) previously equilibrated with 10 mM glycylglycine, pH 7.4. Elution was carried out with stepwise increases in the NaCl concentration: 50 mM, 75 mM, 100 mM, 125 mM, 150 mM and 200 mM. DHAP, GAP and inorganic phosphate (Pi) were eluted with 75 mM NaCl in the same buffer. 3-PG and 1,3-BPG were eluted with 125 and 150 mM NaCl, respectively, in the same buffer. All the compounds thus prepared were stored at ) 80°C until use.
Materials and methods

Materials
Synthesis of [
Analysis of [
32 P] compounds by HPLC Radioactive compounds were analyzed by HPLC on a Whatman Partisil 10 SAX WCS column (4.6 · 250 mm; Beckman Coulter Inc., Fullerton, CA, USA), comparing their retention times with those of non-radioactive authentic standards monitored at 214 nm. The column was equilibrated with 0.4 M sodium phosphate buffer (pH 3.2), and glycolytic intermediates and nucleotides were eluted isocratically, as described previously (Morino et al. 1991) . Retention times for glycolytic intermediates were 4.1 min for DHAP and GAP, 5.3 min for Pi, 5.9 min for 2-phosphoglycerate (2-PG) and 3-PG, 6.0 min for ADP, 7.4 min for phosphoenolpyruvate (PEP), 15.4 min for 1,3-BPG and 30.0 min for ATP.
Preparation of subcellular fractions Subcellular fractions of bovine brain were prepared as described previously (Ueda et al. 1979) . The plasma membrane preparation used in this study was the synaptic plasma membrane M-1 (0.9) fraction obtained upon sucrose density gradient centrifugation. Cytosolic fractions of various rat tissues were prepared as described previously (Ueda and Plagens 1987) . Protein concentration was determined by the method of Bradford (1976) P-labeled protein (30 lg) was incubated at 37°C for 10 s in a mixture (final volume 30 lL) containing 5 mM Tris-maleate (pH 7.4), and indicated concentrations of fructose-1,6-bisphosphate (Fru-1,6-P 2 ) or fructose-2,6-bisphosphate (Fru-2,6-P 2 ). The reaction was terminated by addition of 10 lL sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer, and aliquots (25 lL) were subjected to SDS-PAGE (12% acrylamide) according to the method of Laemmli (1970) , except for omission of sample boiling. Autoradiography was carried out as described previously (Morino et al. 1991) and the amounts of 32 P-labeled protein estimated using an imaging analyzer (Bio-Rad Gel Doc 2000; Bio-Rad Laboratories, Hercules, CA, USA). In some experiments, purified rabbit muscle PGAM (SigmaAldrich, 0.48 U) was used instead of 30 lg synsol protein, and incubated in a reaction mixture containing 5 mM Tris-maleate (pH 7.4), 0.1 mM MgSO 4 , 125 nM 2,3-bisphosphoglycerate (2,3-BPG) and 140 nM (240 Ci/mM) [ Immunoprecipitation Anti-PGAM pAb (10 lg) was absorbed on immobilized protein G (0.1 mL as 50% slurry) and chemically cross-linked using the Seize X mammalian immunoprecipitation kit (Pierce). The synsol fraction (100 lg protein) was incubated at 37°C for 10 s in a mixture (final volume 100 lL) containing 5 mM The reaction mixtures were subjected to immunoprecipitation with immobilized anti-PGAM pAb according to the manufacturer's protocol. Aliquots (20 lL) were subjected to SDS-PAGE (12% acrylamide) according to the method of Laemmli (1970) , except for omission of sample boiling, followed by autoradiography as described previously (Morino et al. 1991) .
Assay for PGAM activity PGAM activity was determined by coupling the formation of 2-PG from 3-PG with the enolase-, pyruvate kinase-and lactate dehydrogenase-catalyzed reactions, according to the method recommended by the International Committee for Standardization in Haematology (Beutler et al. 1977) . Briefly, 100 lg protein of synsol or 0.2 U purified PGAM were incubated in a reaction mixture (final volume, 1 mL) containing 0.1 M Tris-HCl/0.5 mM EDTA (pH 8.0), 2 mM MgCl 2 , 100 mM KCl, 0.2 mM NADH, 1.5 mM neutralized ADP (with NaOH), 10 lM 2,3-BPG, 0.1 mM 3-PG, 1.2 U lactate dehydrogenase, 1.0 U pyruvate kinase and 1.0 U enolase, at 25°C for 10 min. The enzyme activity was calculated from the rate of reduction of NADH by monitoring absorbance at 340 nm.
Radioactive product analysis of the 32 P-labeled PGAM de-labeling reaction PGAM (1.9 mg/mL) was labeled at 37°C for 30 s in a buffer containing 5 mM Tris-maleate (pH 7.4), 125 nM 2,3-BPG, 1 mM MgSO 4 and 0.5 lM [ P]PGAM (175 lg, 40 042 cpm/mg protein) was pre-incubated at 37°C for 30 s in 90 lL 5 mM Tris-maleate (pH 7.4). The reaction was initiated by the addition of 10 lL Fru-2,6-P 2 or 3-PG to indicated final concentrations and allowed to continue for 10 s. The reaction was terminated by addition of 100 lL 30% trichloroacetic acid and centrifuged at 14 000 g max at 4°C. Aliquots (180 lL) of the supernatant fluid were analyzed by HPLC as described above. To analyze the effect of various concentrations of Fru-2,6-P 2 , [ Kinetics study of PGAM 32 P-labeling PGAM (100 lg) was pre-incubated at 37°C for 30 s in 90 lL of reaction mixture containing 5 mM Tris-maleate (pH 7.4), 125 nM 2,3-BPG, 1 mM MgSO 4 and indicated concentrations of Fru-2,6-P 2 . The reaction was initiated by the addition of 10 lL [ 32 P]3-PG to indicated final concentrations and allowed to continue for 10 s. The reaction was terminated by addition of 100 lL 30% trichloroacetic acid and centrifuged at 14 000 g max at 4°C. The pelleted protein was washed with 70% ethanol and radioactivity determined in a scintillation spectrophotometer. (Fig. 1) . As glucose depletioninduced abnormal changes in electroencephalogram and behavior occur within minutes, as does recovery from these deficits observed upon glucose infusion, modification of a protein(s) involved in the mechanism underlying glycolysisdependent synaptic transmission would have to be relatively rapid, as would its de-modification. Time course of 29-kDa protein labeling and de-labeling is shown in Fig. 2 . While the initial rate of labeling is temperature-dependent, the maximal level of labeling is about the same with both incubations at 37°C and 0°C ( Fig. 2) . At 37°C, 32 P-labeling occurs rapidly with s 1/2 of approximately 4 s, whereas the reaction at 0°C is about 10 times slower, with s 1/2 of approximately 45 s. Upon prolonged incubation, the 29-kDa 32 P-protein is de-labeled; at 37°C, de-labeling starts at 2 min, with s 1/2 of approximately 20 min, and at 0°C, it takes place after 15 min.
Results
Labeling
Subcellular and tissue distribution
In order to determine the subcellular distribution of the 29-kDa 32 P-protein, the synsol, pericaryal cytosol, microsomal, synaptic vesicle and plasma membrane fractions were analyzed for labeling with [3-32 P]1,3-BPG. As shown in Fig. 3(a) , the highest level of labeling was observed in the synsol fraction, followed by the pericaryal (cell body) cytosol fraction and the microsomal fraction. The synaptic vesicle and plasma membrane fractions labeled the 29-kDa protein to a minimal extent. In order to determine tissue distribution, various tissues including brain, heart, lung, spleen, pancreas, kidney, liver, muscle and adrenal were homogenized under hypotonic conditions, and the soluble fraction obtained upon ultracentrifugation was analyzed for 29-kDa protein labeling with [3-32 P]1,3-BPG. Brain and the fast-twitch muscle extensor digitorum longus (EDL) exhibited the most intense labeling of 29-kDa protein among all the tissues examined, followed by pancreas (Fig. 3b) . The protein was labeled to a much smaller extent in the spleen, the slow-twitch muscle soleus (SOL) and adrenal. The 29-kDa protein in the heart, lung, kidney and liver was minimally labeled. Similar labeling patterns were observed when tissues were incubated with [ 32 P]3-PG in the presence of 125 nM 2,3-BPG (data not shown).
Effect of glycolytic intermediates and related compounds on labeling of 29-kDa protein
In an effort to explore the possibility that the interaction of the 29-kDa protein with 1,3-BPG, the most minor glycolytic intermediate, is subject to regulation by a step in glucose metabolism, we tested various glycolytic intermediates for the ability to affect 29-kDa protein labeling. As shown in Fig. 4 , the 29-kDa protein labeling was greatly reduced by 3-PG, 2-PG and PEP. Interestingly, Fru-2,6-P 2 also exhibited a marked inhibition; however, its analog Fru-1,6-P 2 was less effective. The 3-PG close analogs GAP, glycerol-3-phosphate and glycerate had no significant effect, however. The effect of PEP could be due to its conversion to 2-PG by enolase present in the synsol preparation.
The strong diminishing effect of 3-PG and 2-PG on 29-kDa protein labeling suggested that this might be PGAM (for review, see Rose 1980; Fothergill-Gilmore and Watson 1989) Fig. 7(a) , the M r s of both proteins were indistinguishable, as judged by SDS-PAGE. The labeling of both proteins was substantially reduced by 3-PG. Fru-2,6-P 2 also affected phosphorylation of both proteins. Moreover, the 29-kDa protein in the synsol fraction labeled with either [3- (Fig. 7b) .
The effect of glycolytic intermediates and related compounds on 32 P-labeling of purified PGAM was examined, in comparison with the effect on 32 P-labeling of the synsol, 29-kDa protein. As shown in Fig. 8 , the inhibition pattern with various glycolytic intermediates and related compounds is very similar to that observed with labeling the 29-kDa protein in the synsol (Fig. 4) , with the exception of the effect of PEP. Although phosphorylation of purified PGAM was inhibited by 3-PG and 2-PG, it was not affected by PEP (Fig. 8) . This is most likely because purified PGAM is largely free of enolase; thus, PEP would not have been converted to 2-PG and hence, not to 3-PG. As a result, isotopic dilution of [ (Fig. 3) was quite striking. In order to determine whether this represents the tissue distribution of PGAM, the cytosolic fractions of various tissues were assayed for PGAM activity. As shown in Fig. 9 , the specific enzyme activity pattern among various tissues tested was similar to the specific 32 P-labeling activity pattern of the cytosolic 29-kDa protein. EDL muscle revealed the highest specific enzyme activity, followed by brain and pancreas; heart, lung, kidney and liver showed the lowest enzyme activity. These observations are consistent with the notion that the cytosolic 32 P-labeled 29-kDa protein is PGAM. P]1,3-BPG at 37°C or 0°C for 10 s in the absence (control) or presence of various glycolytic intermediates and related compounds (50 lM). Aliquots (18.8 lL) were subjected to SDS-PAGE (12%), followed by autoradiography. The level of the 29-kDa 32 P-labeled protein was estimated using an image analyzer as described in Materials and methods, and expressed as the percentage of control value. Values are the mean ± SD of three experiments. Glu, glucose; Glu-1-P, glucose-1-phosphate; Glu-6-P, glucose-6-phosphate; Glu-1,6-P 2 , glucose-1,6-bisphosphate; Fru-1-P, fructose-1-phosphate; Fru-6-P, fructose-6-phosphate; glycerol-3-P, glycerol-3-phosphate.
Fru-2,6-P 2 reduces 32 P-labeling of PGAM by enhancing dephosphorylation As the inhibitory effect of Fru-2,6-P 2 on phosphorylation of PGAM has not been reported, we further studied this property of the enzyme, in comparison with its effect on the 29-kDa protein in the synsol. Shown in Fig. 10 is the effect of various concentrations of Fru-2,6-P 2 on PGAM phosphorylation. The data indicate that Fru-2,6-P 2 quite potently inhibits labeling of the synsol 29-kDa protein and purified PGAM with similar potencies (IC 50 ¼ 8-9 lM). In contrast, Fru-1,6-P 2 was less effective but exhibited similar potencies (IC 50 ¼ 70-80 lM). Fru-2,6-P 2 also inhibited overall enzyme activity in the purified PGAM preparation and in the synsol fraction in a similar manner (Fig. 11) ; however, the IC 50 value of 50 lM was higher than that observed for inhibition of 32 P-labeling. Fru-1,6-P 2 also showed similar inhibitory effects, but with a much lower potency (IC 50 ¼ 1 mM). These observations further argue for the notion that the synsol 29-kDa protein labeled with [3- In an effort to understand the mechanism of inhibition by F-2,6-P 2 , kinetic experiments were carried out on 32 P-labeling and enzyme activity of PGAM, each in the absence or presence of two concentrations of Fru-2,6-P 2 , as shown in Fig. 12 . The data indicate that Fru-2,6-P 2 inhibits both 32 P-labeling and enzyme activity of PGAM in a noncompetitive manner with respect to the substrate 3-PG. The K i was calculated to be 42 lM in the 32 P-labeling reaction and 36 lM in the overall enzyme reaction. These data suggest that Fru-2,6-P 2 produces the inhibitory effect by binding to an allosteric site.
To further understand the action of Fru-2,6-P 2 , we explored the possibility that Fru-2,6-P 2 enhances 32 P-delabeling of PGAM. As shown in Fig. 13 , the 32 P-labeled 29-kDa protein was found to be rapidly de-labeled in the presence of 50 lM Fru-2,6-P 2 , as well as in the presence of 3-PG, not only at 37°C but also at 0°C. The effect of various concentrations of Fru-2,6-P 2 and Fru-1,6-P 2 on de-labeling of the [ 32 P]-labeled 29-kDa protein was examined and compared with the effect on de-labeling of purified 32 P-labeled PGAM (Fig. 14) . Fru-2,6-P 2 was equally potent in the de-labeling of both the 29-kDa protein and PGAM; the concentration required to cause 50% de-labeling was determined to be 1 lM in both cases. Thus, Fru-2,6-P 2 is far more effective in causing de-labeling than in inhibiting [ 32 P]-labeling of the 29-kDa protein.
The radioactive product of the de-labeling reaction was analyzed by HPLC. As shown in Fig. 15(a) , incubation of 32 P-labeled purified PGAM in the presence of Fru-2,6-P 2 resulted in release of [ (Fig. 15b) . In order to correlate [ 32 P]P i release with PGAM de-labeling, the effect of various concentrations of Fru-2,6-P 2 on [ 32 P]P i release was examined (Fig. 15b) in comparison with the effect on PGAM de-labeling. The figure shows that the sensitivity of [ 32 P]P i release from 32 P-labeled PGAM to Fru-2,6-P 2 is indistinguishable from that of PGAM de-labeling to Fru-2,6-P 2 (Fig. 14b) P]3-PG at 37°C for 10 s in the absence (control) or presence of Fru-2,6-P 2 or Fru-1,6-P 2 at the indicated concentrations. Aliquots (18.8 lL) were subjected to SDS-PAGE (12%), followed by autoradiography. The level of 32 P-labeled protein was estimated as the percentage of control value using an image analyzer as described in Materials and methods. Values are the mean ± SD of three experiments. 
Discussion
In an effort to understand a potential biochemical link between glycolysis and synaptic function, in a previous study we sought a glycolytic intermediate-dependent protein phosphorylation system using [c-32 P]ATP. Evidence was obtained for the existence of phosphoglycerate-dependent phosphorylation of 72-kDa and 155-kDa proteins in mammalian brain (Ueda and Plagens 1987; Morino et al. 1991) . The 72-kDa protein was subsequently shown to be directly phosphorylated with [1-32 P]1,3-BPG and identified as glucose 1,6-bisphosphate synthase (Morino et al. 1991) . In contrast, the 155-kDa protein was not subject to direct phosphorylation with [1-32 P]1,3-BPG; hence it is thought to be phosphorylated at the expense of [c- In the present study, we synthesized [3-32 P]1,3-BPG and sought a nerve terminal protein(s) which may be modified by a mechanism involving the transfer of [3-32 P]phosphate or the phosphoglyceroyl moiety. We provided evidence that the major protein labeled with [3- Rose and Dube (1976) , who have shown that both PGAM phosphorylation and dephosphorylation occur rapidly. Moreover, the labeled protein is subject to immunoprecipitation with affinity-purified anti-PGAM IgG. These observations indicate that the [3-32 P]1,3-BPG or [ 32 P]3-PG-labeled 29-kDa protein is identical to PGAM. Thus, labeling and de-labeling of the synsol 29-kDa protein would represent phosphorylation and dephosphorylation of the active site histidine residue of PGAM (Rose 1970 (Rose , 1980 ).
An interesting finding in this study is that Fru-2,6-P 2 inhibits both phosphorylation (IC 50 ¼ 10 lM) and enzymatic activity of PGAM (IC 50 ¼ 50 lM). Fru-2,6-P 2 also accelerates dephosphorylation of PGAM (EC 50 ¼ 1 lM). Fru-2,6-P 2 is more effective in dephosphorylating PGAM than in inhibiting its enzymatic activity. Thus, the apparent diminishing P-labeled protein (1 mg/mL) was incubated at 0°or 37°C for the indicated time in the absence or presence of 50 lM Fru-2,6-P 2 or 3-PG. Aliquots (18.8 lL) were subjected to SDS-PAGE (12%), followed by autoradiography, as described in Materials and methods. The result shown is representative of three separate experiments.
effect of Fru-2,6-P 2 on PGAM phosphorylation could be largely due to its ability to enhance dephosphorylation. In contrast to the case with 3-PG, transfer of radioactive phosphate to Fru-2,6-P 2 was not observed. In fact, Fru-2,6-P 2 stimulated release of inorganic [ (Fig. 15) . Kinetic experiments (Fig. 12) suggest that Fru-2,6-P 2 binds to an allosteric site. These experiments suggest that, upon binding of Fru-2,6-P 2 , PGAM could alter its conformation, exposing the phosphohistidine moiety to the aqueous environment so that the phosphoenzyme is hydrolyzed to inorganic phosphate and dephosphoenzyme.
Fru-2,6-P 2 is known as a regulator of glycolysis in the liver (Van Schaftingen 1987; Okar and Lange 1999) . It acts as an allosteric activator of phosphofructokinase 1 (PFK-1), increasing the enzyme's affinity for fructose 6-phosphate (Van Schaftingen et al. 1981) . In the liver, the biosynthesis of Fru-2,6-P 2 is achieved by phosphofructokinase-2 (PFK-2), whose activity is regulated via phosphorylation of a serine residue by cAMP-dependent protein kinase (Okar et al. 2001) . In the brain, however, PFK-2 activity is not altered as a result of phosphorylation by cAMP-dependent protein kinase Ventura et al. 1992) . Nonetheless, Fru-2,6-P 2 acts as a positive allosteric effector of brain PFK-1 and is thought to play an essential role in the basal activation of the brain enzyme under a variety of physiological conditions (Foe and Kemp 1985; Ventura et al. 1991 ). Brain PFK-1, maximally activated with 4-6 lM Fru-2,6-P 2 , is saturated with Fru-2,6-P 2 under normal conditions (Foe and Kemp 1984; Yamamoto et al. 1990; Ambrosio et al. 1991 Ambrosio et al. , 1992 Ventura et al. 1991; Anglard et al. 1992; Kasten et al. 1993) . Thus, PFK-1 may not be subject to regulation by Fru-2,6-P 2 in the brain under normal conditions .
Fru-2,6-P 2 inhibits PGAM enzyme activity with a K i value of 36 lM. The steady-state tissue level of Fru-2,6-P 2 in the brain is 5-16 nM/g tissue (Yamamoto et al. 1990; Ambrosio et al. 1991 Ambrosio et al. , 1992 Ventura et al. 1991; Kasten et al. 1993) . Neuronal Fru-2,6-P 2 concentration can be increased three to fourfold by treatment with either ACTH or 12-O-tetradecanoylphorbol 13-acetate (Anglard et al. 1992) . Under these conditions, Fru-2,6-P 2 might exert an inhibitory effect on PGAM. Thus, PGAM could be subject to regulation by Fru-2,6-P 2 under certain conditions. Under normal conditions, neuronal PFK-1 would most likely be in a fully activated state in the presence of saturating concentrations of Fru-2,6-P 2 . When PGAM is inhibited by increased concentrations of Fru-2,6-P 2 , the glycolytic intermediate 3-PG would be accumulated. One of the consequences of 3-PG elevation would be to activate 3-PG-dependent protein kinase, leading to phosphorylation of the synsol 155-kDa protein (Ueda and Plagens 1987; Morino et al. 1991) . Thus, it is plausible that glycolysis up to the step of 3-PG production, Fru-2,6-P 2 -induced accumulation of 3-PG and 3-PG-dependent phosphorylation of the 155-kDa protein are all involved in the mechanism underlying glycolysis-dependent synaptic transmission. Further studies are required to determine the significance of PGAM inhibition by Fru-2,6-P 2 .
Another interesting observation is that the level of PGAM labeling with [3-32 P]1,3-BPG, as well as the specific enzyme activity of PGAM, is remarkably high in the brain and the fast-twitch muscle extensor digitorum longus; of brain subcellular fractions, the synsol exhibited the most prominent labeling. The amount of labeled PGAM in the cell body cytosol fraction is substantially smaller. These observations suggest that the rate of glycolysis might be high in subcellular regions where either neurotransmitters or hormones are actively released. It is feasible that in the nerve P-labeled protein of synsol (1 mg/mL) or PGAM (0.016 unit/mL) was incubated at 37°C for 10 s in the absence (control) or presence of Fru-2,6-P 2 or Fru-1,6-P 2 at the indicated concentrations. Aliquots (18.8 lL) were subjected to SDS-PAGE (12%), followed by autoradiography. The level of 32 P-labeled protein was estimated as the percentage of control value, using an image analyzer as described in Materials and methods. Values are the mean ± SD of three experiments.
ending, there is a high demand for glycolytically-produced ATP, rather than ATP produced in mitochondria, in order to meet quick demands for energy; duly responding transmitter release is thus sustained. In further support of this notion is evidence that the nerve ending is rich in glycolytic enzymes (Knull 1978) ; some are associated with the synaptic plasma membrane via actin (Knull 1980) , which would allow glycolysis to occur efficiently at high energy-requiring presynaptic membrane sites. Compatible with this concept, we have recently obtained evidence indicating that glycolyticallygenerated ATP is utilized for neurotransmitter uptake into the releasable vesicular pool (Ikemoto et al. 2003) . Thus, acute depletion of glycolytically-produced ATP, without much affecting the total reserve of ATP which is largely made in mitochondria, would diminish neurotransmitter release. This might provide an explanation for the critical importance of glycolysis in synaptic transmission. The fasttwitch fiber is far richer in glycolytic enzymes, including PGAM, than the slow-twitch fiber of the soleus (Baldwin et al. 1973; Andres et al. 1989) , and is thought to mainly harness glycolytically-produced ATP for rapid muscle movement (Holloszy and Booth 1976) . These lines of evidence are consistent with the notion that rapid, energyconsuming, cellular processes rely on glycolytically-produced ATP. Fru-2,6-P 2 ( M) P to labeled PGAM after incubation at 0°C for indicated periods (b) or with various concentrations of Fru-2,6-P 2 at 37°C for 10 s (c) was measured as described in Materials and methods. Values represent percentage of total labeling of PGAM and the mean ± SD of three experiments.
